Category Archives: Newsroom

Medical Genetic Conference Kuala Lumpur 2022 (MGCKL 2022)

`` The Future Is Now: Challenges and Innovative Solutions in Genetics Diagnostics``

About MGCKL 2022

This 3-day conference will address the challenges and innovate solutions in genetic diagnostics and its achievements. More than 20 speakers will be presenting their views and findings in this conference. The conference will provide opportunities and gather pathologists, maternal-fetal specialists, obstetricians and gynecologists, oncologists, respiratory physicians, pediatric neurologists, clinical geneticists, scientists, laboratory technologies, researches, health practitioners, universities and governments to share their knowledge, experiences and achievements in genetics and its related topics.

Participant

3 Days
  • RM 600
  • Entry to all scientific sessions, Wednesday - Friday
  • Entry to the industry booth exhibition, Wednesday - Friday
  • Morning & afternoon teas and lunches, Wednesday - Friday
  • Name badge & conference book (includes all posters and abstracts)

Student

3 Days
  • RM 350
  • Entry to all scientific sessions, Wednesday - Friday
  • Entry to the industry booth exhibition, Wednesday - Friday
  • Morning & afternoon teas and lunches, Wednesday - Friday
  • Name badge & conference book (includes all posters and abstracts)

Calling for abstract !

The conference organizers cordially invite academics, practitioners, scholars, researchers, policy makers of any government to submit their abstracts in MGCKL2022. Abstracts should be submitted online and will be reviewed by two reviewers. We also welcome and highly encourage postgraduate students to present their research proposal or literature review or findings or issues in this conference with very special registration fees.

 

Submission Deadline:
1st August 2022

Pantai Premier Pathology COVID-19 Journey [May 2021]

Take a journey through PPP’s call of duty ensuring safety & peace of mind amidst the ongoing Pandemic. Let us not be complacent in this fight against Covid-19. Stay vigilant & stay safe!

 

In February 2020, Pantai Premier Pathology (PPP) received approval from the Ministry of Health as one of the 4 private labs in Malaysia to start the COVID-19 screening services. In March 2020, a total of 400 samples were run per day using the rtPCR method. These samples were received from various sites including IHH hospitals, GP clinics and corporate clients. In April 2020, PPP expanded its service offering that includes rtPCR and rapid PCR nationwide with an increase in the running capacity to 800 samples per day. A new service, RTK Antigen, was offered nationwide in May 2020, with increased running capacity to 3,500 per day. PPP has also offered support in running MOH samples when required at that time. A total YTD testing of 7.6% of the nationwide capacity at 207,396 tests was achieved in October 2020 with the launch of another service, RTK Antibody testing. In January 2021, PPP opened up another COVID-19 lab located at Pantai Hospital Ampang. After 12 months of providing COVID-19 screening service, PPP contributed to a total of 460,435 testing nationwide in February 2021. More COVID-19 screening labs were started at Gleneagles Medini, Johor Bahru and KLIA, Sepang in March 2021 with overall running capacity up to 8,000 tests per day. PPP has recorded the highest monthly total sample screened to date at 145,181 in one month as at May 2021.

Pantai Premier Pathology Becomes More Internationally Accessible with Accreditation from College of American Pathologists

IHH Healthcare Malaysia’s laboratory arm, Pantai Premier Pathology, is one of only two laboratories in Malaysia to receive accreditation from the College of American Pathologists (CAP).

 

With this latest accreditation, Pantai Premier Pathology will be able to receive samples from Singapore, Brunei, the Philippines, Taiwan, Indonesia and Vietnam for processing, testing and analysis as these countries, among others, require a laboratory to be accredited by CAP for highest quality assurance. More local and international pharmaceutical companies would also now be open to using the services from Pantai Premier Pathology for their clinical trial testing as CAP accreditation is part of the requirements for certain clinical trials.

 

Now, PPP collaborates extensively with pharmaceutical companies in Malaysia and abroad to conduct clinical trial testing and molecular diagnostic services for cancer patients such as Merck, Pfizer, AstraZeneca, Merck Sharp Dohme (MSD), Novartis, Roche, Amgen and Johnson & Johnson (J&J).

 

Having certified with CAP, PPP is driven to provide excellent patient care while fostering and advocating best practices in pathology and clinical laboratory. This value is reputed to elevate PPP’s prestige in the marketplace to leverage an established partnership by attracting patients, doctors and international partners to collaborate with at which they will receive quality services and accurate results with continuous improvement in customer satisfaction.

 

The CAP received from an internationally recognized organization, endorse PPP to retain business through confidence in its high standard management processes known for its advancement in quality for clinical laboratory. Accreditation by the CAP is therefore seen as an attestation to quality laboratory practices and comes with many advantages. Inspections were conducted by expert teams of multi-disciplinary laboratory professionals to ensure PPP’s standards are compliant with the regulations. This detailed and customized evaluation by the expert teams also ensures that test results are always accurate and thus patients’ diagnoses are also accurate.

 

Pantai Premier Pathology is the only laboratory services provider in Malaysia with four accreditations, including from Joint Commission International, ISO 15189 and the Malaysian Society for Quality in Health. Established in 2016, the laboratory offers diagnostic tests for Pre-Natal, Post-Natal, Haemato-Oncology, Solid Tumour and Infectious Diseases, including COVID-19 testing.

 

 

Media Coverage

The Star:

https://www.thestar.com.my/business/business-news/2021/06/08/ihhs-laboratory-gets-recognition

 

The Sun Daily:

https://www.thesundaily.my/local/ihh-s-laboratory-arm-receive-accreditation-from-cap-NA7938708

 

The Edge Markets:

https://www.theedgemarkets.com/article/ihhs-laboratory-arm-receive-accreditation-cap 

 

 

 

 

Exclusive CME webinar on LIVERFASt

How LIVERFASt can assist you in assessing liver functions in patients at high metabolic (diabetic or obese) risk?

This event is co-organised by Pantai Premier Pathology and Fibronostics.

Dear Dr,

Register now and learn how LIVERFASt can assist you in assessing liver functions in patients at high metabolic (diabetic or obese) risk on Thursday 25th February.

After registration, you will receive a confirmation email containing information and link for joining the webinar.

Thank you and have a good day.

 

FEATURED SPEAKERS

  • Dr Mona MUNTEANU, MD, PhD | Chief Scientific Officer at Fibronostics
  • Dr Ronald QUIAMBAO, MD | Chief Medical Officer at Fibronostics
Event Details
Date:

25th February 2021, Thursday

Time:

12: 00 PM – 2:00 PM (Malaysia Time)

 Program:

12:00 PM  Introductions

12:10 PM  Presentation

1:40 PM    Q&A

2:00 PM    End of webinar

Live Webinar: Interleukin 6

This event is co-organised by Pantai Premier Pathology and SIEMENS.

Learn about the clinical utility and testing considerations for interleukin-6:
• Interleukin-6 (IL-6) has crucial roles in both innate and adaptive immunity.
• IL-6 rises within hours of substantial injury or infection, and may be used as an early indicator of an
acute inflammatory event.
• High IL-6 levels may also reflect a chronic or severe inflammatory state.
• IL-6 may aid in the evaluation for, monitoring, and prognosis for a variety of acute and chronic
diseases associated with inflammation, such as infection, sepsis, autoimmune disease, and
inflammatory bowel disease.
Event Details
Date:

October 14, 2020 (Wednesday)

Time:

1:00 – 2:00 p.m.

Location:

Webinar link will be sent closer to event date.